PDS Biotech Executives Rush to Buy Shares, Betting on a Breakthrough Pipeline Ahead of Next Earnings Flash
Insider stock‑option grants reveal PDS Biotechnology’s confidence in its IL‑12 immunocytokine pipeline and a bullish shift from top execs, hinting at future growth.
3 minutes to read